A retired HGV driver was the first person in the world to take part in a clinical trial to extend the lifespan of blood vessels in the heart, using gene therapy. John MacDonald, 73, suffered a heart ...

Now it means more reach, with a machine learning layer deciding what relevance looks like. Google has been steadily steering advertisers toward fewer moving parts – fewer match types, fewer manual ...

Human gene maps contain major blind spots because they were built largely from the DNA sequences of people with European ancestry, according to a study published in Nature Communications. Researchers ...

“This is not the first time our president has used these insulting and derogatory references and his choices of words have consequences,” Mike Bohacek said iga.in.gov;Steven Hirsch-Pool/Getty ...

President Donald Trump posted a series of anti-immigration messages on Thanksgiving, one of which included a slur. In a Truth Social post, Trump used the "r-word" to describe Minnesota Gov. Tim Walz.

A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients. By Christina Jewett The Food and Drug Administration said on ...

Earlier in the day, Bloomberg columnist Mark Gurman reported that Cupertino intends to pay for an advanced AI model developed by Google, citing people with knowledge of the matter. This model with 1.2 ...

Q. How do the TEXTBEFORE and TEXTAFTER functions in Excel work? A. Excel’s TEXTBEFORE and TEXTAFTER functions allow users to quickly split up text in ways that used to require combinations of ...

AUSTIN, Texas, Oct. 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...

It has been a year since the death of my son. I think about him and miss him every day. Gene was riding his bicycle in Titusville, Florida, when he was struck and killed by a drunk driver. Gene was ...

A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...